With our partner Salesforce, unify sales, marketing and customer service. Accele your growth!
An innovative model at the crossroads of bioinformatics and oncology
Msinsight is part of a new generation of actors combining artificial and bioinformatics intelligence to meet the challenges of medical diagnosis. Its approach is based on the integration of new generation (NGS) and advanced algorithms to improve the identification of microsatellite (MSI) instability cancers.
A diagnosis still too imprecise
Microsatellite instability constitutes a key biomarker for the management of many digestive and gynecological cancers, in particular in the context of immunotherapy treatments. However, current diagnostic techniques have up to 30 % inaccuracy, leading to the therapeutic orientation errors and to the loss of efficiency of treatments. The challenge is twofold: improve the precision of tests and guarantee their large -scale accessibility to optimize care paths.
A standardized bioinformatics solution
MSICARE, the software developed by MSINSIGHT, automatizes and relieves the detection of MSI biomarkers thanks to a fine analysis of genetic sequences. Designed to be integrated into the workflows of laboratories and care centers, it allows a rapid and standardized interpretation of the results, thus reducing diagnostic biases. By relying on artificial intelligence, it improves the sensitivity and specificity of tests, strengthening their clinical relevance for large -scale deployment.
A changing market
With nearly a million new MSI cancer cases identified each year worldwide, demand for precise and reproducible diagnostic solutions continues to grow. The growing use of broadband sequencing in precision medicine accelerates the development of bioinformatic tools capable of optimizing therapeutic targeting. However, regulatory issues remain preponderant: to impose themselves, these technologies must obtain strict certifications, like the CE-IVD marking in Europe or the authorization of the FDA in the United States.
An offer thought for clinical integration
MSICARE is aimed at medical analysis laboratories, hospitals specializing in oncology and research centers, with an economic model based on software licenses and platform integrations. By facilitating the adoption of MSI tests by various medical structures, Msinsight aims to make its solution a standard in the evaluation of MSI cancers, guaranteeing more efficient management of patients.
Recognized scientific and clinical expertise
Founded in 2022, Msinsight benefits from a solid academic foundation, a fruit of two decades of research carried out within Inserm, public assistance – Hospitals of Paris and Sorbonne University. The company is led by Arnaud Cutivet, PHDpresident and co -founder, and Alex Duval, professor and scientific directorspecialist in microsatellite instability in oncology. Around them, a team of experts in bioinformatics and precision medicine contributes to the development and clinical validation of Msicare.
A fundraising to accelerate certification and deployment
Msinsight has just finalized a financing tour of 1.6 million euros in seedled by Calyseedwith the support of Saclay Business Angels, Yes Invest, Capital Cell plateau and bank support of Bpifrance. This funding must make it possible to accelerate CE-IVD certification procedures, an essential condition for large-scale clinical adoption, and to strengthen collaborations with research centers and health establishments.
